Shuk Tak Kwok has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Return to intended oncological therapy following advanced ovarian cancer surgery: a narrative review

    by Ka Yu Tse, Mandy Man Yee Chu, Jessie Wan Kam Chiu, Shuk Tak Kwok, Michael G. Irwin, Aaron Hey Yin Chan, Polly Ho, Calvin Pak Wing Cheng, Siew Fei Ngu, Karen Kar Loen Chan

    Summary: Introduction: Patients with advanced ovarian cancer often require radical cytoreductive surgery and chemotherapy, with or without targeted therapy. Return to intended oncological therapy after surgery is a crucial metric, as delay can worsen survival. The concept of return to intended oncological therapy is important because it highlights the need for not just successful surgical outcomes, but also the ability to continue with the comprehensive cancer treatment plan. Methods: A comprehensive review of the literature was conducted to identify relevant English language studies published from January 2010 to September 2024. Results: Delayed return to intended oncological therapy after surgery was associated with poor survival outcomes in ovarian cancer. This narrative review investigates how pre‐operative counselling and education; optimisation of the patient's medical condition; meticulous surgical planning and execution; early recognition of complications; and comprehensive postoperative care influence return to intended therapy in gynaecological surgery. Effective multidisciplinary care involving anaesthetists; nurses; physiotherapists; dietitians; psychologists; and the patient's relatives or friends, can prevent complications and ensure timely return to intended oncological therapy. Discussion: Awareness and management of factors affecting return to intended oncological therapy are essential for improving outcomes in patients with advanced ovarian cancer. We highlight the importance of multidisciplinary care (including enhanced recovery after surgery programmes) and the factors affecting these including age; nutrition; and occurrence of postoperative complications.


  • Open Access

    Current status and challenges in training the next generation of gynecologic cancer care providers in Asia

    by Jyoti Meena, Dipanwita Banerjee, Se Ik Kim, Hiroaki Komatsu, Shuk Tak Kwok, Yen-Ling Lai, Chia-Sui Weng, Jie Yang, Carolyn Zalameda-Castro, Kittipat Charoenkwan, et al.

    Meena J, et al. J Gynecol Oncol. 2025 Apr;36:e103. https://doi.org/10.3802/jgo.2025.36.e103


  • Open Access

    Patient-Initiated Follow-Up in Ovarian Cancer

    by Hiu Mei Luk, Siew Fei Ngu, Lesley S. K. Lau, Ka Yu Tse, Mandy M. Y. Chu, Shuk Tak Kwok, Hextan Y. S. Ngan, Karen K. L. Chan

    This study aimed to assess the feasibility of patient-initiated follow-up (PIFU) in combination with regular tumour marker monitoring as an alternative to conventional hospital follow-up for ovarian cancer survivors. Women who had recently completed treatment for ovarian cancer and had a raised pre-treatment tumour marker were recruited. Participants were allocated to PIFU (intervention group) or conventional hospital follow-up (control group) according to their own preference. Both groups had regular tumour marker monitoring. The change in fear of cancer recurrence (FCR) score as measured by the FCR inventory, and the supportive care need (SCN) scores as measured by the SCN survey at baseline and at 6 months between PIFU and hospital follow-up were compared. Out of 64 participants, 37 (58%) opted for hospital follow-up and 27 (42%) opted for PIFU. During the 6-month study period, there was no significant difference in the change of FCR between the two groups (p = 0.35). There was a significant decrease in the sexuality unmet needs score in the intervention group from baseline to 6-month FU (mean difference −8.7, 95% confidence interval −16.1 to −1.4, p = 0.02). PIFU with tumour marker monitoring is a feasible follow-up approach in ovarian cancer survivorship care. FCR and SCN were comparable between PIFU and conventional hospital follow-up.


  • Open Access

    Asian Young Doctors Session at the 64th Annual Meeting of the Japanese Society for Gynecologic Oncology (JSGO): Educational Initiatives in the Next Generation for a New Era after the COVID-19 Pandemic

    by Yusuke Kobayashi, Hiroaki Komatsu, Masanori Isobe, Jyoti Meena, Chia-Sui Weng, Se Ik Kim, Jeslyn Jl Wong, Shuk Tak Kwok, Jie Yang, Panida Mathaveechotikul, et al.

    Kobayashi Y, et al. J Gynecol Oncol. 2022 Nov;34(1):e22. https://doi.org/10.3802/jgo.2023.34.e22

  • Open Access

    Applications and Safety of Sentinel Lymph Node Biopsy in Endometrial Cancer

    by Wan Kam Chiu, Shuk Tak Kwok, Yaokai Wang, Hiu Mei Luk, Aaron Hei Yin Chan, Ka Yu Tse

    Lymph node status is important in predicting the prognosis and guiding adjuvant treatment in endometrial cancer. However, previous studies showed that systematic lymphadenectomy conferred no therapeutic values in clinically early-stage endometrial cancer but might lead to substantial morbidity and impact on the quality of life of the patients. The sentinel lymph node is the first lymph node that tumor cells drain to, and sentinel lymph node biopsy has emerged as an acceptable alternative to full lymphadenectomy in both low-risk and high-risk endometrial cancer. Evidence has demonstrated a high detection rate, sensitivity and negative predictive value of sentinel lymph node biopsy. It can also reduce surgical morbidity and improve the detection of lymph node metastases compared with systematic lymphadenectomy. This review summarizes the current techniques of sentinel lymph node mapping, the applications and oncological outcomes of sentinel lymph node biopsy in low-risk and high-risk endometrial cancer, and the management of isolated tumor cells in sentinel lymph nodes. We also illustrate a revised sentinel lymph node biopsy algorithm and advocate to repeat the tracer injection and explore the presacral and paraaortic areas if sentinel lymph nodes are not found in the hemipelvis.


  • Open Access

    Diagnostic Performance of Risk of Malignancy Algorithm (ROMA), Risk of Malignancy Index (RMI) and Expert Ultrasound Assessment in a Pelvic Mass Classified as Inconclusive by International Ovarian Tumour Analysis (IOTA) Simple Rules

    by Siew Fei Ngu, Yu Ka Chai, Ka Man Choi, Tsin Wah Leung, Justin Li, Gladys S. T. Kwok, Mandy M. Y. Chu, Ka Yu Tse, Vincent Y. T. Cheung, Hextan Y. S. Ngan, et al.

    The accurate prediction of malignancy for a pelvic mass detected on ultrasound allows for appropriate referral to specialised care. IOTA simple rules are one of the best methods but are inconclusive in 25% of cases, where subjective assessment by an expert sonographer is recommended but may not always be available. In the present paper, we evaluate the methods for assessing the nature of a pelvic mass, including IOTA with subjective assessment by expert ultrasound, RMI and ROMA. In particular, we investigate whether ROMA can replace expert ultrasound when IOTA is inconclusive. This prospective study involves one cancer centre and three general units. Women scheduled for an operation for a pelvic mass underwent a pelvic ultrasound pre-operatively. The final histology was obtained from the operative sample. The sensitivity, specificity and accuracy for each method were compared with the McNemar test. Of the 690 women included in the study, 171 (25%) had an inconclusive IOTA. In this group, expert ultrasound was more sensitive in diagnosing a malignant mass compared to ROMA (81% vs. 63%, p = 0.009) with no significant difference in the specificity or accuracy. All assessment methods involving IOTA had similar accuracies and were more accurate than RMI or ROMA alone. In conclusion, when IOTA was inconclusive, assessment by expert ultrasound was more sensitive than ROMA, with similar specificity.